IDH1 and cholangiocarcinoma: Several targeted therapies have received approval for cholangiocarcinoma treatment (see Table 30), including inhibitors of FGFR (futibatinib, pemigatinib, and infigratinib), IDH1 (ivosidenib), and MSI-high/TMB-high (pembrolizumab), and NTRK (larotrectinib, entrectinib).